You are here

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.

Last updated on February 22, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Enterprise, Alabama, 36330 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Overactive Bladder
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Adult subjects with overactive bladder symptoms (subject-reported) for greater than or
equal to 3 months prior to Screening/Enrollment visit.

- Reported at least an average of 1 UUI episode per 24 hours in the 3-day bladder diary
prior to the Randomization/Baseline visit

- Mean urinary frequency of greater than or equal to 8 micturitions per 24 hours as
verified by the 3-day bladder diary prior to randomization/Baseline visit.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subjects with any condition that would contraindicate their usage of fesoterodine
including: hypersensitivity to the active substance (fesoterodine fumarate) or to
peanut or soya or any of the excipients, urinary retention, gastric retention,
uncontrolled narrow angle glaucoma, myasthenia gravis, severe hepatic impairment
(Child Pugh C), severe ulcerative colitis, and toxic megacolon.

- Subjects with clinically significant hepatic or renal disease or other significant
unstable diseases.

- OAB symptoms caused by neurological conditions, known pathologies of urinary tract,
etc.

- Subjects with previous history of acute urinary retention requiring catheterization,
or severe voiding difficulties in the judgment of the investigator, prior to baseline.

NCT00611026
Pfizer
Completed
Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now